To the Editor: A 38-year-old man with genotype 1b chronic hepatitis C infection had been treated with 48 weeks of pegylated interferon (IFN)-α and ribavirin. Autoimmune serology performed just before treatment showed positive perinuclear antineutrophil cytoplasmic antibodies (ANCA) accompanied by an elevated antimyeloperoxidase antibody level (22 U/mL; reference range [RR], < 5 U/mL). Notably, the patient was ANCA-negative 12 months previously. The treatment course was uneventful.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Dumoulin FL, Leifeld L, Sauerburch T, Spengler U. Autoimmunity induced by Interferon-αlpha therapy for chronic viral hepatitis. Biomed Pharmacother 1999; 53: 242-254.
- 2. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26 (3 Suppl 1): 112S-121S.
- 3. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-1893.
No relevant disclosures.